Patients
21.8 per 100,000 people
Suicide rate, Russia, 2023 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Russia ADHD Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$148.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $198.9 Mn | — | — |
| 2025 (base) | $211.1 Mn | +$12.1 Mn | — |
| 2026 (forecast) | $223.9 Mn | +$12.9 Mn | +6.1% |
| 2027 (forecast) | $237.6 Mn | +$13.7 Mn | +12.6% |
| 2028 (forecast) | $252.1 Mn | +$14.5 Mn | +19.4% |
| 2029 (forecast) | $267.5 Mn | +$15.4 Mn | +26.7% |
| 2030 (forecast) | $283.8 Mn | +$16.3 Mn | +34.5% |
| 2031 (forecast) | $301.1 Mn | +$17.3 Mn | +42.7% |
| 2032 (forecast) | $319.5 Mn | +$18.4 Mn | +51.4% |
| 2033 (forecast) | $339.0 Mn | +$19.5 Mn | +60.6% |
| 2034 (forecast) | $359.6 Mn | +$20.7 Mn | +70.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $211.1 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $359.6 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Attention Deficit Hyperactivity Disorder (ADHD) Drugs |
| Segments | Drug type, age and end user (see all) |
| Key players | Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, Supernus Pharmaceuticals, Teva Pharmaceutical (see all) |
| Regulator in Russia | Ministry of HealthSource: Ministry of Health of the Russian Federation. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
ADHD drugs treat attention deficit hyperactivity disorder in children and adults with stimulant and non-stimulant medicines.
Key segments of the ADHD Drugs market include drug type (Stimulants and Non-Stimulants) and age (Children, Adolescents and Adults).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the ADHD Drugs market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the ADHD Drugs market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the ADHD Drugs market.
The ADHD Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are registered by the Ministry of Health, under Eurasian Economic Union rules.[1] Compulsory medical insurance (OMS) pays for a guaranteed package of free care, through the Federal Compulsory Medical Insurance Fund.[2] Suicide rate: 21.8 per 100,000 people in 2023, the latest WHO figure for Russia.[3]
[1] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[2] Federal Compulsory Medical Insurance Fund. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for ADHD Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Russia.
What doctors and scientists are doing in ADHD Drugs right now, from free public sources.
21.8 per 100,000 people
Suicide rate, Russia, 2023 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
Russia · 3 shared keywords
Russia · 2 shared keywords
Russia · 2 shared keywords
Russia · 2 shared keywords
Russia · 2 shared keywords
Russia · 2 shared keywords
OTC & Nutraceuticals · Russia
Digital Health · Russia
Digital Health · Russia
OTC & Nutraceuticals · Russia
Healthcare Services · Russia
Healthcare Services · Russia